CRBU
Caribou Biosciences, Inc.
There isn't enough reported data to score CRBU yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CRBU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CRBU's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CRBU PE Valuation
CRBU has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CRBU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CRBU's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CRBU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.03 | +$0.67 |
| Q2 2026 | -$1.08 | +$0.70 |
| Q1 2026 | -$1.42 | +$0.20 |
| Q4 2025 | -$1.59 | +$0.06 |
| Q3 2025 | -$1.70 | -$0.12 |
| Q2 2025 | -$1.78 | -$0.46 |
| Q1 2025 | -$1.62 | -$0.24 |
| Q4 2024 | -$1.65 | -$0.27 |
CRBU is still losing money, but far less than before: $1.03 per share over the past year, against $2.86 at its worst in late 2021.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CRBU on earnings quality, reporting a profit while its opponent remains loss making.
CRBU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -27% |
| Q2 2026 | $1.5M | -44% |
| Q1 2026 | $2.4M | +1.9% |
| Q4 2025 | $3.9M | +90% |
| Q3 2025 | $2.2M | +8.6% |
| Q2 2025 | $2.7M | -23% |
| Q1 2025 | $2.4M | -3.1% |
| Q4 2024 | $2.1M | -42% |
CRBU's revenue fell from its 2023 peak and has held roughly level since: $2M last quarter, down 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1720% | -383 points |
| Q2 2026 | -1690% | +94 points |
| Q1 2026 | -1096% | +727 points |
| Q4 2025 | -722% | +1150 points |
| Q3 2025 | -1338% | +552 points |
| Q2 2025 | -1784% | -528 points |
| Q1 2025 | -1824% | +70 points |
| Q4 2024 | -1872% | -819 points |
CRBU's operating margin was −1720% last quarter, down 383 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CRBU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CRBU on profitability, with a higher operating margin.
CRBU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.5M | +$2.8M |
| Q2 2026 | -$22.8M | +$5.9M |
| Q1 2026 | -$27.1M | +$10.7M |
| Q4 2025 | -$20.6M | +$15.4M |
| Q3 2025 | -$25.3M | +$8M |
| Q2 2025 | -$28.7M | +$6.4M |
| Q1 2025 | -$37.8M | +$884K |
| Q4 2024 | -$36M | -$12.3M |
CRBU has burned cash in almost every quarter: −$93M over the past year, against −$128M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CRBU on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRBU Net Leverage
CRBU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CRBU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 1.8 | Oversold |
CRBU's weekly RSI is 26 (oversold) and its Stochastic is 2 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CRBU PE vs Healthcare Sector
CRBU has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CRBU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.65 | 42% below |
| 20 week MA | $1.21 | 69% below |
| 50 week MA | $1.57 | 76% below |
| 100 week MA | $1.56 | 76% below |
| 200 week MA | $2.98 | 87% below |
CRBU is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CRBU on trend strength, trading above more of its moving averages.
CRBU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.3 | $16.2 | -0.9% |
| 2022 | $16.2 | $6.16 | -62% |
| 2023 | $6.16 | $5.73 | -7% |
| 2024 | $5.73 | $1.67 | -71% |
| 2025 | $1.67 | $1.70 | +1.8% |
| 2026 YTD | $1.70 | $0.38 | -78% |
CRBU has finished lower in four of the last five years. It's down 78% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CRBU on returns for 2026, with the stronger performance.